Developer docs
API playgroundTry for free, no card

Search company profiles

Black Diamond Therapeutics

Full company profile

uuid0003e89

Namestring
Black Diamond Therapeutics
Legal namestring
Black Diamond Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Black Diamond Therapeutics is a clinical-stage oncology company headquartered at 245 First Street, Cambridge, MA, founded to develop "MasterKey" therapies, targeted small-molecule inhibitors designed to address broad genetically defined cancer populations, overcome acquired resistance (including C797S), minimize wild-type mediated toxicities, and penetrate the blood-brain barrier for CNS disease. Its pipeline centers on silevertinib (BDTX-1535), a brain-penetrant fourth-generation EGFR inhibitor in Phase 2 development for EGFR-mutant non-small cell lung cancer and glioblastoma, with reported Phase 2 data of 60% objective response rate, 91% disease control rate, 86% CNS response rate, and 15.2 months median progression-free survival in first-line NSCLC patients with non-classical EGFR mutations. The company also has BDTX-4876 (FGFR inhibitor) in earlier-stage development, and previously held BDTX-4933 (a brain-penetrant MasterKey RAF inhibitor), which was out-licensed to Servier in March 2025.

The company is incorporated in the United States and trades on Nasdaq under ticker BDTX. As a pre-commercial biotech, it generates no product revenue and historically funded operations through venture capital, an IPO completed in 2020, and a $75.0 million public offering in June 2023. Its go-to-market model is clinical-stage biotech: identifying mutation-defined responder populations, conducting multi-site Phase 2 trials in the United States (with active engagement for an ex-US partner on the global first-line NSCLC trial), presenting data at major oncology congresses including ASCO, AACR, ESMO, SNO, and EANO, and pursuing partnership transactions for assets outside the lead EGFR franchise, exemplified by the Servier deal.

Financially, Black Diamond reported $70.0 million of license revenue in 2025 from the Servier transaction, swinging to $22.4 million of net income versus a $69.7 million net loss in 2024. Cash, cash equivalents, and investments stood at $128.7 million at year-end 2025 and $118.3 million at Q1 2026, with management guiding runway into the second half of 2028. Stock trades at a $207 million market capitalization as of May 2026, having returned approximately 72% over the prior twelve months on the back of positive silevertinib data.

Short descriptiontext

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, brain-penetrant targeted inhibitors for broad genetically defined cancer populations. Its lead asset silevertinib targets EGFR-mutant non-small cell lung cancer and glioblastoma. Headquartered in Cambridge, MA; Nasdaq: BDTX.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted oncology therapeutics, precision cancer drugs, EGFR inhibitor development, kinase inhibitor platform, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAH
Neuro-Oncology
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Revenue
TypeLicensing Royalties
Description

The company recognized $70 million in license revenue in 2025, indicating successful out-licensing of technology. BDTX-4933 was out-licensed to Servier in March 2025.

biospace.com
2Public Equity Offering
TypeOne Time License
Description

Company raised approximately $75.0 million in gross proceeds through public offering of 15 million shares at $5.00 per share in June 2023.

investors.blackdiamondtherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Black Diamond Therapeutics develops MasterKey-targeted cancer therapies, with its lead clinical-stage drug candidate silevertinib (BDTX-1535), a brain-penetrant fourth-generation EGFR inhibitor being studied for non-small cell lung cancer and glioblastoma. The company additionally advances BDTX-4933 (a RAF inhibitor out-licensed to Servier) and BDTX-4876 (an FGFR inhibitor) through its pipeline, with revenue currently generated via out-licensing arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60% objective response rate in first-line NSCLC patients with non-classical EGFR mutations (Phase 2, 43 patients)
+3 more records
Product overview1 text field

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies—targeted cancer treatments designed to address broad genetically defined patient populations, overcome resistance mechanisms, minimize wild-type mediated toxicities, and penetrate the blood-brain barrier to treat CNS diseases. The company's pipeline includes three clinical-stage programs: silevertinib (BDTX-1535), a fourth-generation EGFR inhibitor for NSCLC and GBM; BDTX-4933, a RAF inhibitor out-licensed to Servier; and BDTX-4876, an FGFR inhibitor. The MasterKey approach aims to expand the addressable patient population by targeting multiple mutations with a single therapeutic solution.

Product and service3 records
1Silevertinib (BDTX-1535)
CategoryClinical-stage drug candidate (oncology)
Description

A brain-penetrant fourth-generation EGFR MasterKey inhibitor in Phase 2 clinical development for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The drug targets EGFR mutations including classical, non-classical, and the C797S resistance mutation, and is being evaluated in combination with temozolomide in newly diagnosed GBM and as monotherapy in EGFR-mutant NSCLC.

2BDTX-4933
CategoryClinical-stage drug candidate (out-licensed oncology asset)
Description

An oral, brain-penetrant MasterKey inhibitor of Class I, II, and III oncogenic RAF mutations with preclinical data demonstrating a potential best-in-class profile. The asset was out-licensed to Servier in March 2025, generating license revenue and validating the MasterKey platform.

3BDTX-4876
CategoryPipeline drug candidate (oncology)
Description

An FGFR (Fibroblast Growth Factor Receptor) inhibitor program in the company's pipeline, developed under the MasterKey approach to targeting oncogenic mutations in cancer.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-01
Description

BDTX-4933, an oral brain-penetrant MasterKey inhibitor targeting Class I, II, and III oncogenic RAF mutations, was out-licensed to Servier in March 2025. This partnership leverages Servier's resources for further development of the RAF inhibitor program while Black Diamond focuses on its EGFR programs (silevertinib).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Nuvalent
TypeDirect peer
Description

Clinical-stage oncology company developing parallel fourth-generation kinase inhibitors for NSCLC, including EGFR and ALK programs. Closest direct comparable given overlapping EGFR mutation coverage, brain-penetrant design, and similar NSCLC focus.

TypeBroad incumbent
Description

Maker of Tagrisso (osimertinib), the dominant first-line EGFR-mutant NSCLC therapy. The principal incumbent competitor Black Diamond must differentiate against in NSCLC.

TypeBroad incumbent
Description

Large oncology player with multiple targeted therapy programs (post-Seagen acquisition). Represents the broad-pharma competitive backdrop and potential acquirer profile.

TypeDirect peer
Description

Precision oncology company using computational approaches to develop therapies against oncogenic mutations including PI3Kα and FGFR. Comparable as a clinical-stage precision oncology peer with similar size and strategy.

TypeBroad incumbent
Description

Established precision oncology company with multiple approved kinase inhibitors (AYVAKIT, GAVRETO). Comparable as a larger precision oncology peer operating in similar targeted-therapy space.

TypeEmerging player
Description

Clinical-stage oncology company developing kinase inhibitors (e.g., bezuclastinib for systemic mastocytosis and GIST). Comparable as a similarly-sized clinical-stage precision oncology peer.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on the MAP kinase pathway, including EGFR and RAF targets that overlap with Black Diamond's pipeline. Comparable as a similarly-sized clinical-stage oncology peer.

TypeBroad incumbent
Description

Global oncology player with a sizable targeted therapy franchise and history of bolt-on acquisitions in clinical-stage oncology. Relevant as potential partner/acquirer and as a broad competitor.

TypeDirect peer
Description

Precision oncology company developing targeted therapies against RAS/MAPK pathway mutations. Comparable as a mid-cap clinical-stage oncology peer with platform-based mutation targeting and similar lung cancer adjacency.

TypeBroad incumbent
Description

Acquired by Bristol Myers Squibb in 2024 for ~$4.8B. Previously a direct NSCLC EGFR/KRAS-adjacent competitor; serves as a useful reference for how large pharma values clinical-stage targeted oncology assets of comparable profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Black Diamond Therapeutics

Targeted Oncology Therapeuticsblackdiamondtherapeutics.com

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, brain-penetrant targeted inhibitors for broad genetically defined cancer populations. Its lead asset silevertinib targets EGFR-mutant non-small cell lung cancer and glioblastoma. Headquartered in Cambridge, MA; Nasdaq: BDTX.

What Black Diamond Therapeutics does

Black Diamond Therapeutics is a clinical-stage oncology company headquartered at 245 First Street, Cambridge, MA, founded to develop "MasterKey" therapies, targeted small-molecule inhibitors designed to address broad genetically defined cancer populations, overcome acquired resistance (including C797S), minimize wild-type mediated toxicities, and penetrate the blood-brain barrier for CNS disease. Its pipeline centers on silevertinib (BDTX-1535), a brain-penetrant fourth-generation EGFR inhibitor in Phase 2 development for EGFR-mutant non-small cell lung cancer and glioblastoma, with reported Phase 2 data of 60% objective response rate, 91% disease control rate, 86% CNS response rate, and 15.2 months median progression-free survival in first-line NSCLC patients with non-classical EGFR mutations. The company also has BDTX-4876 (FGFR inhibitor) in earlier-stage development, and previously held BDTX-4933 (a brain-penetrant MasterKey RAF inhibitor), which was out-licensed to Servier in March 2025.

The company is incorporated in the United States and trades on Nasdaq under ticker BDTX. As a pre-commercial biotech, it generates no product revenue and historically funded operations through venture capital, an IPO completed in 2020, and a $75.0 million public offering in June 2023. Its go-to-market model is clinical-stage biotech: identifying mutation-defined responder populations, conducting multi-site Phase 2 trials in the United States (with active engagement for an ex-US partner on the global first-line NSCLC trial), presenting data at major oncology congresses including ASCO, AACR, ESMO, SNO, and EANO, and pursuing partnership transactions for assets outside the lead EGFR franchise, exemplified by the Servier deal.

Financially, Black Diamond reported $70.0 million of license revenue in 2025 from the Servier transaction, swinging to $22.4 million of net income versus a $69.7 million net loss in 2024. Cash, cash equivalents, and investments stood at $128.7 million at year-end 2025 and $118.3 million at Q1 2026, with management guiding runway into the second half of 2028. Stock trades at a $207 million market capitalization as of May 2026, having returned approximately 72% over the prior twelve months on the back of positive silevertinib data.

Black Diamond Therapeutics firmographics

Firmographics
Name
Black Diamond Therapeutics
Legal name
Black Diamond Therapeutics, Inc.
Website
https://blackdiamondtherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies, brain-penetrant targeted inhibitors for broad genetically defined cancer populations. Its lead asset silevertinib targets EGFR-mutant non-small cell lung cancer and glioblastoma. Headquartered in Cambridge, MA; Nasdaq: BDTX.
Ownership category
akta.pro rank

Black Diamond Therapeutics industry classification

Industry
Product category
Targeted Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAH
Neuro-Oncology
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Targeted oncology therapeutics
  • Precision cancer drugs
  • EGFR inhibitor development
  • Kinase inhibitor platform
  • Clinical-stage biopharmaceuticals

Where Black Diamond Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Black Diamond Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Licensing Revenue: The company recognized $70 million in license revenue in 2025, indicating successful out-licensing of technology. BDTX-4933 was out-licensed to Servier in March 2025.
  2. Public Equity Offering: Company raised approximately $75.0 million in gross proceeds through public offering of 15 million shares at $5.00 per share in June 2023.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Black Diamond Therapeutics product offering

Product offering

Core offering

Black Diamond Therapeutics develops MasterKey-targeted cancer therapies, with its lead clinical-stage drug candidate silevertinib (BDTX-1535), a brain-penetrant fourth-generation EGFR inhibitor being studied for non-small cell lung cancer and glioblastoma. The company additionally advances BDTX-4933 (a RAF inhibitor out-licensed to Servier) and BDTX-4876 (an FGFR inhibitor) through its pipeline, with revenue currently generated via out-licensing arrangements.

Product overview

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies—targeted cancer treatments designed to address broad genetically defined patient populations, overcome resistance mechanisms, minimize wild-type mediated toxicities, and penetrate the blood-brain barrier to treat CNS diseases. The company's pipeline includes three clinical-stage programs: silevertinib (BDTX-1535), a fourth-generation EGFR inhibitor for NSCLC and GBM; BDTX-4933, a RAF inhibitor out-licensed to Servier; and BDTX-4876, an FGFR inhibitor. The MasterKey approach aims to expand the addressable patient population by targeting multiple mutations with a single therapeutic solution.

Differentiator

Problem solved

Functional benefit

Products and services

  • Silevertinib (BDTX-1535) A brain-penetrant fourth-generation EGFR MasterKey inhibitor in Phase 2 clinical development for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The drug targets EGFR mutations including classical, non-classical, and the C797S resistance mutation, and is being evaluated in combination with temozolomide in newly diagnosed GBM and as monotherapy in EGFR-mutant NSCLC.
  • BDTX-4933 An oral, brain-penetrant MasterKey inhibitor of Class I, II, and III oncogenic RAF mutations with preclinical data demonstrating a potential best-in-class profile. The asset was out-licensed to Servier in March 2025, generating license revenue and validating the MasterKey platform.
  • BDTX-4876 An FGFR (Fibroblast Growth Factor Receptor) inhibitor program in the company's pipeline, developed under the MasterKey approach to targeting oncogenic mutations in cancer.

Quantifiable outcome

  • 60% objective response rate in first-line NSCLC patients with non-classical EGFR mutations (Phase 2, 43 patients)
  • +3 more outcomes

Companies that use Black Diamond Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Black Diamond Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Black Diamond Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ServiercoreOEM/ Whitelabel/ Licensing Partner · 1 March 2025BDTX-4933, an oral brain-penetrant MasterKey inhibitor targeting Class I, II, and III oncogenic RAF mutations, was out-licensed to Servier in March 2025. This partnership leverages Servier's resources for further development of the RAF inhibitor program while Black Diamond focuses on its EGFR programs (silevertinib).

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Black Diamond Therapeutics competitors and assessment

Company assessment

Direct peers

  • Nuvalent: Clinical-stage oncology company developing parallel fourth-generation kinase inhibitors for NSCLC, including EGFR and ALK programs. Closest direct comparable given overlapping EGFR mutation coverage, brain-penetrant design, and similar NSCLC focus.
  • Relay Therapeutics: Precision oncology company using computational approaches to develop therapies against oncogenic mutations including PI3Kα and FGFR. Comparable as a clinical-stage precision oncology peer with similar size and strategy.
  • Erasca: Clinical-stage precision oncology company focused on the MAP kinase pathway, including EGFR and RAF targets that overlap with Black Diamond's pipeline. Comparable as a similarly-sized clinical-stage oncology peer.
  • Revolution Medicines: Precision oncology company developing targeted therapies against RAS/MAPK pathway mutations. Comparable as a mid-cap clinical-stage oncology peer with platform-based mutation targeting and similar lung cancer adjacency.

Broad incumbents

  • AstraZeneca: Maker of Tagrisso (osimertinib), the dominant first-line EGFR-mutant NSCLC therapy. The principal incumbent competitor Black Diamond must differentiate against in NSCLC.
  • Pfizer: Large oncology player with multiple targeted therapy programs (post-Seagen acquisition). Represents the broad-pharma competitive backdrop and potential acquirer profile.
  • Blueprint Medicines: Established precision oncology company with multiple approved kinase inhibitors (AYVAKIT, GAVRETO). Comparable as a larger precision oncology peer operating in similar targeted-therapy space.
  • Takeda: Global oncology player with a sizable targeted therapy franchise and history of bolt-on acquisitions in clinical-stage oncology. Relevant as potential partner/acquirer and as a broad competitor.
  • Mirati Therapeutics: Acquired by Bristol Myers Squibb in 2024 for ~$4.8B. Previously a direct NSCLC EGFR/KRAS-adjacent competitor; serves as a useful reference for how large pharma values clinical-stage targeted oncology assets of comparable profile.

Emerging players

  • Cogent Biosciences: Clinical-stage oncology company developing kinase inhibitors (e.g., bezuclastinib for systemic mastocytosis and GIST). Comparable as a similarly-sized clinical-stage precision oncology peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Black Diamond Therapeutics social profiles

Digital presence

Black Diamond Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Black Diamond Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Black Diamond Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Black Diamond Therapeutics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Black Diamond Therapeutics

What does Black Diamond Therapeutics do?

Black Diamond Therapeutics develops MasterKey-targeted cancer therapies, with its lead clinical-stage drug candidate silevertinib (BDTX-1535), a brain-penetrant fourth-generation EGFR inhibitor being studied for non-small cell lung cancer and glioblastoma. The company additionally advances BDTX-4933 (a RAF inhibitor out-licensed to Servier) and BDTX-4876 (an FGFR inhibitor) through its pipeline, with revenue currently generated via out-licensing arrangements.

Is Black Diamond Therapeutics a public or private company?

Black Diamond Therapeutics is a public company. It is classified as public and is currently operating.

When was Black Diamond Therapeutics founded?

Black Diamond Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Black Diamond Therapeutics based?

Black Diamond Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Black Diamond Therapeutics make money?

Two revenue lines are on record. Licensing Revenue is the primary driver. The others are public Equity Offering.

Who are Black Diamond Therapeutics's main competitors?

Direct peers on record are Nuvalent, Relay Therapeutics, Erasca and Revolution Medicines. Broad incumbents are AstraZeneca, Pfizer, Blueprint Medicines, Takeda and Mirati Therapeutics. Cogent Biosciences is listed as an emerging player.

Does Black Diamond Therapeutics have an API?

No public API is recorded for Black Diamond Therapeutics.

What industry is Black Diamond Therapeutics in?

Black Diamond Therapeutics's product category is Targeted Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comBlack Diamond Therapeutics at Jefferies: FDA path lifts silevertinib hopesBlack Diamond Therapeutics said the FDA supported an accelerated approval path for silevertinib in non-classical EGFR mutant NSCLC, using CNS response rate as the primary endpoint. The company reported an 86% CNS response rate and a planned 300-patient Phase III trial starting in Q2 2027, with CNS data expected in 2029. The company has $102 million in cash, funding operations through H2 2028.Investing.comBlack Diamond Therapeutics at Stifel 2026: FDA path sharpensBlack Diamond Therapeutics outlined an FDA-backed accelerated approval path for silevertinib in EGFR-mutant NSCLC with brain metastases, citing an 86% CNS response rate and 12.2-month median PFS. The company plans a Phase III trial starting Q2 2025 and needs additional capital to reach approval milestones.BenzingaWhy Is Black Diamond Therapeutics Stock Soaring Tuesday? - Black Diamond Therapeutic (NASDAQ:BDTX)Black Diamond Therapeutics reported updated Phase 2 data for silevertinib in non-small cell lung cancer, showing a 60% overall response rate and 93% disease control. The FDA supported its Phase 3 program, with a global trial planned for Q2 2027. The company expects cash to fund operations into H2 2028.Seeking AlphaBlack Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans TranscriptBlack Diamond Therapeutics held a webcast on November 10, 2026, to present updated Phase II results for silevertinib in frontline non-small cell lung cancer patients. The company also outlined its pivotal development plans and provided a brief update on its glioblastoma program.Quiver QuantitativeBlack Diamond Reports $10.0 Million Q3 Loss and Updated Silevertinib Data | BDTX Stock NewsBlack Diamond Therapeutics reported a Q3 2026 net loss of $10.0 million, down from $8.5 million a year earlier, with $102.0 million in cash. Updated Phase 2 silevertinib data showed 60% ORR in EGFR non-classical mutation NSCLC, and the company expects its Phase 3 trial to begin in Q2 2027.Seeking AlphaBlack Diamond: Delay In Trial Results Leads To Downgrade, But It's Still A Buy (BDTX)Black Diamond Therapeutics was downgraded from Strong Buy to Buy due to a slower-than-expected phase 3 initiation for silevertinib in 1st-line non-classical EGFRm NSCLC. The drug showed a 60% overall response rate and 86% CNS response in phase 2. Key catalysts in Q4 2026 include updated phase 2 data and FDA feedback on advancing to a pivotal phase 3 trial.American Banking and Market NewsBlack Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Reaffirmed as “Buy” by HC WainwrightHC Wainwright reaffirmed a "buy" rating on Black Diamond Therapeutics, while other analysts gave mixed ratings. The stock opened at $1.78, with an average price target of $11.00 and an average rating of "Moderate Buy." The company reported a loss of $0.17 per share for the quarter, beating the consensus estimate.MarketBeatHC Wainwright Reaffirms "Buy" Rating for Black Diamond Therapeutics (NASDAQ:BDTX)HC Wainwright reaffirmed a Buy rating for Black Diamond Therapeutics, while other firms issued mixed ratings. The stock has a consensus price target of $11.00 and a Moderate Buy rating, with 95.47% institutional ownership. The company reported a quarterly loss of $0.17 per share, beating estimates.MarketBeatBlack Diamond Therapeutics (BDTX) Projected to Announce Earnings on ThursdayBlack Diamond Therapeutics is projected to announce Q3 2026 earnings on Thursday, November 5th, with expected EPS of -$0.0550 and revenue of $8.33 million. The stock opened at $1.83, and analysts have an average rating of Moderate Buy with a target price of $11.00.MarketBeatBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock Has Consensus Target Price of $11.00Black Diamond Therapeutics shares have a consensus Moderate Buy rating with an average 1-year price objective of $11.00. The stock opened at $1.83, with a market cap of $105.13 million and a P/E ratio of -2.44. The company reported a quarterly loss of $0.17 per share, beating the consensus estimate of -$0.20.